TRAW (Traws Pharma, Inc. Common Stock) Stock Analysis - AI Report

Traws Pharma, Inc. Common Stock (TRAW) is a publicly traded Healthcare sector company. As of May 21, 2026, TRAW trades at $1.70 with a market cap of $26.67M and a P/E ratio of -0.94. TRAW moved +3.14% today. Year to date, TRAW is +25.58%; over the trailing twelve months it is +29.60%. Its 52-week range spans $0.97 to $19.44. Rallies surfaces TRAW's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on TRAW?

Rallies AI research for TRAW combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

TRAW Key Metrics

Key financial metrics for TRAW
MetricValue
Price$1.70
Market Cap$26.67M
P/E Ratio-0.94
EPS$-1.71
Dividend Yield0.00%
52-Week High$19.44
52-Week Low$0.97
Volume3.27K
Avg Volume0
Revenue (TTM)$2.73M
Net Income$-19.43M
Gross Margin0.00%

Latest TRAW News

Recent TRAW Insider Trades

  • ORBIMED ADVISORS LLC bought 597.73K (~$998.21K) on Apr 16, 2026.

TRAW Analyst Consensus

TRAW analyst coverage data. Average price target: $0.00.

Common questions about TRAW

What is the AI research view on TRAW?
Rallies AI research for TRAW combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for TRAW?
Rallies AI research for TRAW combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is TRAW research on Rallies investment advice?
No. Rallies provides research, data, and educational context for TRAW. It does not provide personalized investment advice.
TRAW

TRAW